Representative Josh Gottheimer (D-New Jersey) recently sold shares of Sysmex Corporation ADR OTCMKTS: SSMXY. In a filing disclosed on September 05th, the Representative disclosed that they had sold between $1,001 and $15,000 in Sysmex stock on August 21st. The trade occurred in the Representative's "MORGAN STANLEY - SELECT UMA ACCOUNT # 1" account.
Representative Josh Gottheimer also recently made the following trade(s):
- Purchased $1,001 - $15,000 in shares of Natera NASDAQ: NTRA on 8/22/2025.
- Sold $1,001 - $15,000 in shares of Visa NYSE: V on 8/12/2025.
- Sold $1,001 - $15,000 in shares of International Business Machines NYSE: IBM on 8/12/2025.
- Sold $1,001 - $15,000 in shares of Visa NYSE: V on 8/1/2025.
- Sold $1,001 - $15,000 in shares of Walmart NYSE: WMT on 7/28/2025.
- Sold $1,001 - $15,000 in shares of International Business Machines NYSE: IBM on 7/25/2025.
- Sold $1,001 - $15,000 in shares of Natera NASDAQ: NTRA on 7/22/2025.
- Sold $1,001 - $15,000 in shares of Abbott Laboratories NYSE: ABT on 7/18/2025.
- Sold $1,001 - $15,000 in shares of Independence Realty Trust NYSE: IRT on 7/16/2025.
- Sold $1,001 - $15,000 in shares of Visa NYSE: V on 7/14/2025.
Sysmex Stock Performance
OTCMKTS:SSMXY opened at $13.31 on Tuesday. Sysmex Corporation ADR has a 1 year low of $12.50 and a 1 year high of $22.00. The business has a fifty day simple moving average of $15.13 and a two-hundred day simple moving average of $16.95. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.37 and a quick ratio of 2.49. The company has a market capitalization of $8.38 billion, a P/E ratio of 26.62 and a beta of 1.10.
Sysmex (OTCMKTS:SSMXY - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported $0.05 EPS for the quarter, missing analysts' consensus estimates of $0.12 by ($0.07). Sysmex had a return on equity of 10.20% and a net margin of 9.35%.The company had revenue of $717.09 million during the quarter, compared to the consensus estimate of $807.27 million. On average, analysts expect that Sysmex Corporation ADR will post 0.57 earnings per share for the current year.
Analysts Set New Price Targets
Separately, Zacks Research raised Sysmex from a "strong sell" rating to a "hold" rating in a report on Thursday, August 14th. One research analyst has rated the stock with a Hold rating, According to data from MarketBeat, the stock has an average rating of "Hold".
View Our Latest Analysis on Sysmex
About Representative Gottheimer
Josh Gottheimer (Democratic Party) is a member of the U.S. House, representing New Jersey's 5th Congressional District. He assumed office on January 3, 2017. His current term ends on January 3, 2027.
Gottheimer (Democratic Party) is running for re-election to the U.S. House to represent New Jersey's 5th Congressional District. He declared candidacy for the 2026 election.
Gottheimer is also running for election for Governor of New Jersey. He declared candidacy for the Democratic primary scheduled on June 10, 2025.
Gottheimer attended the University of Pennsylvania for his undergraduate degree. He became a Thouron Fellow at Oxford and attended Harvard Law School. Gottheimer worked as a speech writer under former President Bill Clinton (D), assisting with two State of the Union addresses, among other projects. Before running for Congress, he worked for Microsoft as a general manager for corporate strategy.
Sysmex Company Profile
(
Get Free Report)
Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Sysmex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sysmex wasn't on the list.
While Sysmex currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.